27th Jul 2015 09:25
LONDON (Alliance News) - PureTech Health PLC on Monday said its Gelesis Inc subsidiary has outlined plans to expand its ongoing weight loss study for the Gelesis100 product.
Gelesis has received confirmation from the US Food and Drug Administration that the weight loss study is a non-significant device study, which means the company can expand it to further states.
Gelesis100 is a treatment which works to induce weight loss and improve glycemic control.
"The expansion of Gelesis' clinical study to serve as a pivotal trial enables Gelesis to accelerate the timeline and potentially bring this important new therapy to the market even sooner," said Daphne Zohar, PureTech's chief executive.
Shares in PureTech were up 3.0% to 152.50 pence on Monday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech